Product Description: Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
CAS Number: 2981469-90-1
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Target: Interleukin Related